Education
About Us
Working with TipRanks
Follow Us
Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $9.65
Previous CloseN/A
Volume307.14K
Average Volume (3M)541.67K
Market Cap
$1.97M
Enterprise Value-$2.35M
Total Cash (Recent Filing)$5.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 09, 2025EPS Estimate
-1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.04
Shares Outstanding2,765,980
10 Day Avg. Volume1,347,429
30 Day Avg. Volume541,670
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.78
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.42
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$8.00Price Target Upside1026.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive preliminary safety results from Phase 1 study indicate that PALI-2108 was well-tolerated with no treatment related adverse events or serious adverse events.
Market OpportunityThe global inflammatory bowel disease market is estimated at over $20 billion, presenting a significant market opportunity for PALI-2108 if successful.
Bears Say
Financial PerformancePalisade reported 3Q24 results with a net loss of ($3.5M) and ended the period with $8.0M in cash, which should provide sufficient funding into 2Q25.
Stock PerformancePALI shares have traded down since the spring and the company will have to conduct another financing in the near-term, which can occur in various forms.
---
Ownership Overview
0.79% Insiders
0.53% Mutual Funds
3.81% Other Institutional Investors
94.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.70 and its highest was $9.65 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $1.97M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is May 09, 2025 which is in 45 days.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -1.99.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 2,765,980 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
---
Company Description
Palisade Bio
Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect and repair the gastrointestinal (GI) mucosal barrier. The company operates in the healthcare sector, specifically targeting GI health to improve patient outcomes in various conditions, including post-operative GI complications. Palisade Bio's core product pipeline includes therapies designed to reduce inflammation and improve healing processes in the GI tract, addressing unmet medical needs with innovative solutions.
---
PALI Stock 12 Month Forecast
Average Price Target
$8.00
▲(1026.76% Upside)
Technical Analysis
Ardelyx
―
Ascendis Pharma
―
Voyager Therapeutics
―
Bioxcel Therapeutics
―
Mirum Pharmaceuticals
―
Best Analysts Covering PALI
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-79.85%
reiterated a buy rating 4 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.85% per trade.
---